Selgantolimod
- Generic Name
- Selgantolimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20FN5O
- CAS Number
- 2004677-13-6
- Unique Ingredient Identifier
- RM4GJT3SMQ
- Background
Selgantolimod is under investigation in clinical trial NCT03491553 (Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-suppressed Adults With Chronic Hepatitis B).
- Associated Conditions
- -
- Associated Therapies
- -
Hepatitis B Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals
Hepatitis B, a significant global health challenge, is expected to see market growth due to increasing prevalence and awareness. Key companies like Gilead Sciences and Brii Biosciences are advancing treatments through clinical trials. The market, driven by antiviral medications, anticipates a surge with new pipeline products. Vaccination remains the most effective prevention method.
Gilead to Present Latest Research Across Key Liver Disease Indication at the American ...
Gilead Sciences to present over 40 abstracts at The Liver Meeting® 2024, including new data on primary biliary cholangitis (PBC) and hepatitis Delta virus (HDV), highlighting ongoing commitment to liver disease research.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath